Antigen Discovery Inc - formerly dba ImmPORT Therapeutics Inc - is described as a proteome company providing research services and products The firm specializes in high throughput protein microarray technology designed to simplify proteomic biomarker discovery and to enable the serological and immune profiling of whole proteomes. The firm's proteome microarray approach is designed significantly to decrease the time and cost required to perform proteome-wide antigen screening by eliminating time consuming steps in traditional cloning, protein expression and screening methodologies. ADIs flexible and robust microarray platform facilitates the discovery of diagnostic biomarkers, vaccine candidates, as well as therapeutic antibody discovery and target validation.
